logo
Twitter
Discord
Email
logo
logo
Avadel Pharmaceuticals plcNASDAQ - AVDL
Reports
Search reports
Name
Reporting Date
Filing Date
2024-09-30 10-Q2024-09-302024-11-12
2024-06-30 10-Q2024-06-302024-08-08
2024-03-31 10-Q2024-03-312024-05-08
2023-12-31 10-K2023-12-312024-04-26
2023-12-31 10-K2023-12-312024-02-29
2023-09-30 10-Q2023-09-302023-11-08
2023-06-30 10-Q2023-06-302023-08-09
2023-03-31 10-Q2023-03-312023-05-04
2022-12-31 10-K2022-12-312023-03-29
2022-09-30 10-Q2022-09-302022-11-09
2022-06-30 10-Q2022-06-302022-08-09
2022-03-31 10-Q2022-03-312022-05-09
2021-12-31 10-K2021-12-312022-03-16
2021-09-30 10-Q2021-09-302021-11-08
2021-06-30 10-Q2021-06-302021-08-09
2021-03-31 10-Q2021-03-312021-05-10
2020-12-31 10-K2020-12-312021-03-09
2020-09-30 10-Q2020-09-302020-11-09
2020-06-30 10-Q2020-06-302020-08-10
2020-03-31 10-Q2020-03-312020-05-11
1
2
3
20 / page
About
Name
Avadel Pharmaceuticals plc
Overview
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Show More
CEO
Mr. Gregory J. Divis Jr.
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NASDAQ
Listing Date
1996-06-07
Address
10 Earlsfort Terrace, Dublin, 2, Ireland
Tel
353-1-901-5201
Website
https://www.avadel.com